National Health (Pharmaceutical Benefits – early supply) Amendment Instrument 2018 (No. 7) (PB 65 of 2018) (Cth)

PB 65 of 2018

National Health (Pharmaceutical Benefits – early supply) Amendment Instrument 2018 (No. 7)

National Health Act 1953

___________________________________________________________________________

I, LISA LA RANCE, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

Dated 27 JULY 2018

LISA LA RANCE

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

___________________________________________________________________________

1. Name of Instrument

(1)This Instrument is the National Health (Pharmaceutical Benefits – early supply) Amendment Instrument 2018 (No. 7).

(2)This Instrument may also be cited as PB 65 of 2018.

1. Commencement

This Instrument commences on 1 August 2018.

1. Amendment of National Health (Pharmaceutical Benefits—early supply) Instrument 2015 (PB 120 of 2015)

Schedule 1 amends the National Health (Pharmaceutical Benefits—early supply) Instrument 2015 (PB 120 of 2015).

Schedule 1       Amendments

1. Schedule 1, after entry for Ibrutinib

insert:

Ibrutinib Capsule 140 mg 20 120 5

1. Schedule 1, entry for Levodopa with carbidopa and entacapone

(a)omit from the column headed “Form”:       Tablet 100 mg‑25 mg‑200 mg

substitute:   Tablet 100 mg‑25 mg (as monohydrate)‑200 mg

(b)omit from the column headed “Form”:       Tablet 125 mg‑31.25 mg-200 mg

substitute:   Tablet 125 mg‑31.25 mg (as monohydrate)‑200 mg

(c)omit from the column headed “Form”:       Tablet 150 mg‑37.5 mg -200 mg

substitute:   Tablet 150 mg‑37.5 mg (as monohydrate)‑200 mg

(d)omit from the column headed “Form”:       Tablet 200 mg‑50 mg-200 mg

substitute:   Tablet 200 mg‑50 mg (as monohydrate)‑200 mg

(e)omit from the column headed “Form”:       Tablet 50 mg‑12.5 mg-200 mg

substitute:   Tablet 50 mg‑12.5 mg (as monohydrate)‑200 mg

(f)omit from the column headed “Form”:       Tablet 75 mg‑18.75 mg-200 mg

substitute:   Tablet 75 mg‑18.75 mg (as monohydrate)‑200 mg

1. Schedule 1, entry for Methyldopa

omit from the column headed “Form”:     Tablet 250 mg

substitute:   Tablet 250 mg (as sesquihydrate)

1. Schedule 1, after entry for Pirfenidone

insert:

Pirfenidone	Tablet 267 mg	20	270	5
Pirfenidone	Tablet 801 mg	20	90	5

1. Schedule 1, entry for Pramipexole

(a)omit from the column headed “Form”:       Tablet (extended release) containing pramipexole hydrochloride 1.5 mg

substitute:   Tablet (extended release) containing pramipexole dihydrochloride monohydrate 1.5 mg

(b)omit from the column headed “Form”:       Tablet (extended release) containing pramipexole hydrochloride 2.25 mg

substitute:   Tablet (extended release) containing pramipexole dihydrochloride monohydrate 2.25 mg

(c)omit from the column headed “Form”:       Tablet (extended release) containing pramipexole hydrochloride 3 mg

substitute:   Tablet (extended release) containing pramipexole dihydrochloride monohydrate 3 mg

(d)omit from the column headed “Form”:       Tablet (extended release) containing pramipexole hydrochloride 3.75 mg

substitute:   Tablet (extended release) containing pramipexole dihydrochloride monohydrate 3.75 mg

(e)omit from the column headed “Form”:       Tablet (extended release) containing pramipexole hydrochloride 4.5 mg

substitute:   Tablet (extended release) containing pramipexole dihydrochloride monohydrate 4.5 mg